Patents by Inventor Mark A. Thiede

Mark A. Thiede has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Production of megakaryocytes by the use of human mesenchymal stem cells
    Patent number: 7153500
    Abstract: The present invention is directed to hematopoietic progenitor cells isolated from a tissue specimen, such as marrow cells or peripheral blood, and to the method of co-culturing isolated hematopoietic progenitor cells with human mesenchymal stem cells to induce megakaryocyte differentiation and platelet production. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate blood disorders.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: December 26, 2006
    Assignee: Osiris Therapeutics
    Inventors: Pankaj Qasba, Mark A. Thiede
  • Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
    Patent number: 6255112
    Abstract: The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: July 3, 2001
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark A. Thiede, Gabriel Mbalaviele
  • Production of megakaryocytes by the use of human mesenchymal stem cells
    Publication number: 20010005591
    Abstract: The present invention is directed to hematopoietic progenitor cells isolated from a tissue specimen, such as marrow cells or peripheral blood, and to the method of co-culturing isolated hematopoietic progenitor cells with human mesenchymal stem cells to induce megakaryocyte differentiation and platelet production. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate blood disorders.
    Type: Application
    Filed: February 9, 2001
    Publication date: June 28, 2001
    Applicant: Osiris Therapeutics, Inc.
    Inventors: Pankaj Qasba, Mark A. Thiede
  • Production of megakaryocytes by the use of human mesenchymal stem cells
    Patent number: 6225119
    Abstract: The present invention is directed to hematopoietic progenitor cells isolated from a tissue specimen, such as marrow cells or peripheral blood, and to the method of co-culturing isolated hematopoietic progenitor cells with human mesenchymal stem cells to induce megakaryocyte differentiation and platelet production. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate blood disorders.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: May 1, 2001
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Pankaj Qasba, Mark A. Thiede
  • Vitro maintenance of hematopoietic stem cells
    Patent number: 6030836
    Abstract: The present invention is directed to human mesenchymal stem cells isolated from a tissue specimen, such as marrow cells, and to the method of co-culturing isolated mesenchymal stem cells and/or mesenchymal stem cell-derived adipocytes with hematopoietic progenitor cells such that the hematopoietic stem cells retain their phenotype.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: February 29, 2000
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark A. Thiede, Mark F. Pittenger, Gabriel Mbalaviele
  • Method of isolating mesenchymal stem cells associated with isolated megakaryocytes by isolating megakaryocytes
    Patent number: 5965436
    Abstract: The present invention is directed to isolated and purified human mesenchymal stem cells, to a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i.e. mesenchymal stem cells or "MSCs"), and to the characterization of and uses for such cells. In particular, the invention relates to isolation of MSCs that are associated with hematopoietic cells, such as megakaryocyte precursors, in the bone marrow.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: October 12, 1999
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark A. Thiede, Daniel R. Marshak